Jesber Completes Tens of Millions RMB Series A+ Financing as a Leading Domestic Platform with Full-Core Spine Endoscopy Technology

VCBeat has learned thatSuzhou Jiesbyer Medical Technology Co., Ltd. (hereinafter referred to as "Jiesbyer") recently announcedCompleted a tens-of-millions-of-RMB A+ round of financing led by Dalton Venture, with Life Capital serving as the exclusive financial advisor for this round.Primary Use of Financing ProceedsTo further strengthen the company’s leading position in providing comprehensive solutions for spinal endoscopy, primarily through expanding production capacity, registering new products, and enhancing market promotion.

Jiesbyer Medical is an innovative technology company dedicated to the field of full-endoscopic spine surgery. Founded by a professional technical team with over 20 years of deep expertise in the domestic endoscopy sector and extensive experience and resources in spinal endoscopic techniques, the company possesses profound capabilities in the integrated development of complex products spanning electronics, engineering, optics, software, mechanics, ergonomics, and energy technologies. Jiesbyer Medical is the only company, aside from the renowned German endoscopy manufacturer RIWOspine (a wholly-owned subsidiary of WOLF), that has mastered the complete core technologies for spinal endoscopy.

Percutaneous endoscopic spine surgery is a novel minimally invasive treatment for lumbar disc herniation and spinal stenosis that have proven refractory to conservative management, and it is currently recognized as the most effective minimally invasive technique in spinal surgery. The spinal endoscopy industry has experienced rapid growth in recent years. According to incomplete statistics, the annual volume of percutaneous endoscopic spine surgeries in China has surged from fewer than 10,000 procedures a few years ago to over 100,000 currently, with double-digit annual growth rates. It is projected that within the next 5–10 years, spinal endoscopic surgeries will account for 50–60% of the spinal surgery market.

The company’s product portfolio encompasses energy-based devices, spinal endoscopes, endoscopic camera systems, powered surgical instruments, and endoscopic implants. It provides a comprehensive range of equipment and consumables required for percutaneous full-endoscopic spine surgery and endoscopic spinal fusion procedures, positioning itself as a total solution provider with core proprietary technologies.

Jiesbyer Medical’s independently developed series of percutaneous spinal endoscopes comprehensively covers all types and specifications of endoscopes available on the market. Featuring a fully self-designed optical system, these devices are capable of withstanding high-temperature and high-pressure sterilization. Their patented structural design mitigates the risks of spinal canal and intracranial hypertension caused by intraoperative irrigation.

The ultrasonic bone power system, independently developed over a period of one and a half years, is also a flagship product. It integrates five functions—ultrasonic, powered, shaving, irrigation pump, and negative pressure—into a single unit. Compared to single-function ultrasonic bone scalpels currently on the market, it not only reduces surgical operation time for physicians but also resolves the issue of blurred vision during the resection of bony tissue, as well as the inconvenience of selecting among multiple foot pedals during surgery.

In addition to the aforementioned products, Jiesbyer Medical has launched a leading fully endoscopic 360° minimally invasive spinal fusion system. For patients with milder symptoms, the company’s independently developed interbody cages enable non-instrumented fusion, eliminating the need for pedicle screw-rod fixation. This approach offers minimal tissue trauma, lower costs, and favorable prognosis, truly embodying the concept of endoscopic minimally invasive surgery. The system is also compatible with traditional interbody cages, allowing for full endoscopic visualization throughout the procedure. It is anticipated that in the near future, fully endoscopic implementations of existing ALIF, XLIF, DLIF, and OLIF techniques will be achieved.

Leveraging its comprehensive product portfolio covering the entire spinal endoscopy industry chain, Jiesbyer Medical has established collaborations with numerous renowned hospitals and experts in China, assisting clinical specialists in promoting and popularizing this innovative technology. By holding a substantial portfolio of core technical patents, Jiesbyer Medical has successfully exported its spinal endoscopy products and technologies to traditional powerhouses in endoscopic technology overseas. Through strategic alliances with international partners, the company is driving global sales and clinical adoption of its products. Beyond full-endoscopic spine solutions, the company will continue to expand its layout into UBE (Unilateral Biportal Endoscopy) spinal endoscopy, 3DME microscopic endoscopy, sports medicine arthroscopy systems, and orthopedic robotics (navigation and surgery). By learning from advanced international concepts and technologies, Jiesbyer Medical aims to sustain its innovation capabilities while actively engaging in exchanges and cooperation in the global market, striving to become a global leader in the endoscopy field representing “Made in China.”

Hu Shanyun, Founder, Chairman, and General Manager of Jiesbyer MedicalIndicates:With 20 years of dedication to endoscopic technology, spinal surgery has entered a new era of endoscopy. Spinal endoscopic procedures are experiencing rapid growth, driven by advantages such as minimal invasiveness, faster recovery, and favorable prognosis. Since its inception, the company has prioritized addressing core clinical needs as the driving force behind its development, while leveraging independent innovation and R&D capabilities as the fundamental source of its international competitiveness. We extend our sincere gratitude to Dalton Venture for their strong confidence in the company during this funding round, and to Life Capital for their professional support throughout the financing process. Looking ahead, we aim to collaborate with more industry partners and investors to build a world-class, internationally competitive Chinese enterprise specializing in spinal endoscopy.

Sun Qi, Managing Partner at Dalton Venture, stated:Minimally invasive therapy represents the inevitable trend and direction of surgical treatment. As a highly effective minimally invasive technique in spinal surgery, percutaneous endoscopic spine surgery is undergoing rapid development globally. Currently, the predominant technologies and products still originate from overseas companies. Jiesbyer Medical is the domestic company with the most comprehensive product portfolio in this field, boasting over 20 years of deep expertise and abundant resources in endoscopic technology. Chinese-made innovative medical devices are entering their most promising period of development. We believe that the growth of Jiesbyer Medical will benefit a greater number of orthopedic patients in China.

Li Hao, Founder of Life Capital, stated:The spinal endoscopy industry is in a period of rapid development. Currently, the domestic market is still dominated by imported products, but we believe that Chinese manufacturers with core innovative technologies have significant growth potential. Furthermore, as policies such as the “Two-Invoice System,” centralized procurement, and DRG-based payment are implemented, the bargaining power of single-product device manufacturers has weakened. Policies are favoring leading enterprises, while small-scale, single-product device manufacturers face high operational costs. In centralized procurement, platform-type enterprises can build their own barriers by adopting more flexible product portfolio and pricing strategies. Under DRG bundled payment systems, platform-type enterprises can reduce hospitals’ procurement costs by providing comprehensive solutions. Therefore, we remain long-term bullish on the development of medical device platform companies with sustained innovation capabilities.